ATTACHMENT_B_DATA_CHARACTERISTICS_TABLE.pdf
PDF 110 KB Posted
- Solicitation number
- FDA-RFP-1168334
About this file
Attachment B Data Characteristics Table
View the file
Other files
| File | Type | Posted |
|---|---|---|
| Amendment_3_Responses_to_Questions.pdf | ||
| Attachment_C_Pricing_Table_(2).xlsx | XLSX spreadsheet | |
| FDA-RFP-1168344_(2).pdf | ||
| Attachment_D_Past_Performance_Questionnaire_(2).docx | DOCX document | |
| ATTACHMENT_D-_Past-Performance-Questionnaire.doc | DOC document | |
| FDA-RFP-1168334.pdf | ||
| FDA-RFP-1168344.pdf | ||
| Attachement_A_Glossary.pdf | ||
| Attachment_C_Pricing_Table.xlsx | XLSX spreadsheet | |
| ATTACHMENT_D-_Past-Performance-Questionnaire.doc | DOC document |
On GovTribe
Work with this file
- Download the original file
- Contacts named in this file
- Similar government files
- Ask GovTribe AI about this file
Text version
ATTACHMENT B - DATA CHARACTERISTICS TABLE
Addiction Treatment Center Data Procurement Data Characteristics Table
Overall Database Characteristics:
Month and year when data collection began The total number of years of data available The ability to provide electronic datasets [Y/N]
The lag time between date of data collection and availability for analysis
Description of data de-identification method
Checks on data continuity and completeness [Y/N]
Past history of data revisions and/or re-releases, and process for dealing with large-scale database errors.
Site Characteristics:
The geographic locations (distribution by state) of participating sites for each quarter of the most recent complete year of available data The cumulative distribution function of number of subjects per site, per quarter for the most recent year of available data ( i .e. for each number of subjects (x-axis), the number of sites who have that number of subjects or less (y-axis) )
Subject Characteristics:
Number of assessments or surveys completed per quarter in the most recent complete year of available data, by:
• Age (10-year increments)
• Gender
• Race/Ethnicity
• Facility type where assessment took place (e.g. OTP/methadone, inpatient/residential, etc.)
• Geographic region of client residence (HHS regions: http://www.hhs.gov/about/regionmap.html)
• Class of primary substance abused (e.g. prescription opioids, heroin, cocaine, alcohol, etc.)
Mean, median, mode and range of the number of assessments completed per subject for the most recent complete year of available data Overall number of subjects and assessments represented in the entire database
Instrument and Data Element Characteristics:
A copy of the most recent version of the survey instrument or assessment tool A description of the abuse outcomes, including how they are defined using the instrument (including any algorithms) and the validity of these outcomes. Include any white papers or published articles describing validation of the survey instrument or assessment tool outcomes/measures.
Describe any assessments of product specificity or product-level misclassification, including the impact on the individual product abuse estimates.
Availability of strengths of reported pharmaceutical products abused [Y/N] Availability of formulation of active ingredients (e.g. extended release, potentially abuse-deterrent formulations) [Y/N] Availability of product brand, branded generic, or generic name [Y/N] Abil ity to stratify by primary and secondary substances of abuse [Y/N] The percentage of missing or incomplete information for each data element (for the most recent complete year of available data) Complete data dictionary The frequency with which the instrument is updated and a description of the process and timing of how these updates are distributed to participating sites.
File details come from the government source that posted it. Updated .